Medical/Pharmaceuticals

TraceLink Announces 2025 Corporate Grant Recipients Driving Global Community Impact

Through this annual program, TraceLink champions global health equity, community resilience, and shared purpose Summary TraceLink announced the eight global nonprofit recipients of its 2025 corporate grant program, supporting organizations in the U.S.,India, and Spain and providing volunteer opp...

2025-12-02 23:00 1056

Frost & Sullivan: Health Recovery Solutions Receives the 2025 North American Customer Value Leadership Recognition for Excellence in Patient-Centered Care Delivery

Frost & Sullivan recognizes Health Recovery Solutions for delivering adaptable, outcomes-driven, technology-enabled longitudinal care models SAN ANTONIO, Dec. 2, 2025 /PRNewswire/ -- Frost & Sullivan

2025-12-02 21:30 887

Neusoft Medical Systems Unveils World's First 8cm Wide-Coverage Photon-Counting CT and Other Premium Innovations at RSNA 2025

CHICAGO, Dec. 2, 2025 /PRNewswire/ -- Neusoft Medical Systems Co., Ltd. ("Neusoft Medical"), a global leader in medical imaging, is showcasing its comprehensive portfolio of intelligent healthcare innovations at the Radiological Society ofNorth America (RSNA) 2025 annual meeting. The highlight o...

2025-12-02 17:26 1153

Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy

SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...

2025-12-02 17:00 2078

Accord Healthcare Announces Launch of Denosumab∇ - Second Biosimilar in Bone Health

∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. LONDON, Dec. 2, 2025 /PRNewswire/ -- Accord Healthcare today announced the launch of Osvyrti (denosumab), a biosimilar to Prolia® (Amgen), and Jubereq (denosumab), a biosimilar to...

2025-12-02 15:00 1119

Amaran Biotech's Vaccine Adjuvant AB-801 Receives FDA Drug Master File (DMF) Filing Acknowledgement

HSINCHU, Dec. 2, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced that its self-developed, GMP-grade high-purity vaccine adjuvantAB-801 has received an Acknowledgement Letter from the U.S. Food and Drug Administration (FD...

2025-12-02 14:42 966

Chula's Deep GI: AI Revolutionizes Gastrointestinal Cancers Detection

BANGKOK, Dec. 2, 2025 /PRNewswire/ -- The Faculty of Medicine , Chulalongkorn University , in collaboration with the Faculty of Engineering , has developed "Deep GI

2025-12-02 10:40 1767

Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006

HANGZHOU, China and SHANGHAI and BOSTON, Dec. 2, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today ann...

2025-12-02 08:00 2242

Ziwig Endotest®: Scientific Validation Published in NEJM Evidence

LYON, France, Dec. 2, 2025 /PRNewswire/ -- NEJM Evidence, a journal of the New England Journal of Medicine Group, has published an article titled "Validation of a Saliva microRNA Signature for Endometriosis," dedicated to the saliva-based diagnostic test developed by Ziwig. The publication repor...

2025-12-02 06:00 974

CQ Medical® Expands Radiation Therapy Portfolio With Bionix Business Unit Acquisition

AVONDALE, Pa., Dec. 2, 2025 /PRNewswire/ -- CQ Medical, the global leader in patient radiotherapy positioning and healthcare innovation, is proud to announce the acquisition of Bionix's Radiation Therapy business unit, marking an expansion of its patient positioning and marking product portfolio....

2025-12-02 02:07 884

Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI

SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-acting anti-TSLP antibody, marking a pivotal step as GB-0895 advances the pro...

2025-12-01 19:00 1325

Lee's Pharm Supports Disaster Relief Efforts for Wang Fuk Court in Tai Po

HONG KONG, Dec. 1, 2025 /PRNewswire/ -- Lee's Pharmaceutical Holdings Limited (" Lee's Pharm" or the "Group", stock code: 0950.HK) expresses its deep condolences to the victims of the serious fire at Wang Fuk Court inTai Po, which caused multiple casualties and left many residents homeless and in ...

2025-12-01 18:46 1198

Hedia appoints new CEO: Rasmus Kofoed to succeed Lars Christian Lund

COPENHAGEN, Denmark, Dec. 1, 2025 /PRNewswire/ -- Danish diabetes‑tech company Hedia is implementing a leadership change effective1 December 2025, when Rasmus Kofoed will take over as Chief Executive Officer (CEO). He succeeds Lars Christian Lund, who after approximately 2 years in the role has d...

2025-12-01 16:00 1125

The Wisdom Derived from the Great Migration: Hakka Medicine - The Unique "Medical Epic" of the Hakka People

HONG KONG, Dec. 1, 2025 /PRNewswire/ -- From November 23rd to 25th, the 7th World Hakka Conference was held in Meizhou,Guangdong. With the theme "Gathering Global Hakka Businesspeople to Foster High-Quality Development," the conference adhered to the principles of "openness, innovation, cooperati...

2025-12-01 15:26 1577

Oxford Instruments launches Imaris 11: boosting research productivity with clear, workflow-driven image analysis

LONDON, Dec. 1, 2025 /PRNewswire/ -- Oxford Instruments announces the release of Imaris 11, the latest generation of its industry-leading 3D/4D microscopy image visualisation and analysis software. The new version introduces an intuitive Workflow system, enhanced batch processing, and advanced to...

2025-12-01 09:00 1430

MetaOptics Announces Strategic Share Placement to Accelerate Growth and Meet Rising Global Demand

SINGAPORE, Dec. 1, 2025 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) (" MetaOptics" or the "Company", and together with its subsidiaries, the "Group"), a leading-edge semiconductor optics company, announced that it is proposing to raiseS$4.85 million through a placement of 6,685,028 new ordinary...

2025-12-01 08:30 2547

The Science of Longevity: Inside Prof. Mike Chan's Vision for Living Stronger, Smarter, and Longer

BANGKOK, Dec. 1, 2025 /PRNewswire/ -- Malaysia had a rare moment of reflection this year when former Prime Minister Tun Dr. Mahathir Mohamad turned 100. His milestone sparked public conversations about aging, vitality, and what it truly means to remain strong at any age.

2025-12-01 00:57 1952

The Bioregenerative Sports Revolution: How Prof. Mike Chan Is Changing Athlete Recovery -- From Sabah to the Super Bowl

KOTA KINABALU, Malaysia, Dec. 1, 2025 /PRNewswire/ -- Big changes often start in small ways. For Sabah FC, a top Malaysian football club, it began with a simple agreement — a partnership with European Wellness, a medical group best known for anti-aging and precursor stem cell therapy.

2025-12-01 00:27 2027

Perlis Royalty Join Prof. Mike Chan in Strengthening Malaysia's Fight Against Autism

KUALA LUMPUR, Malaysia, Nov. 30, 2025 /PRNewswire/ -- Malaysia's drive to modernize autism care received strong support today when the Raja Muda of Perlis, Tuanku Syed Faizuddin Putra Jamalullail, and his consort, Tuanku Dr. Hajah Lailatul Shahreen Akashah Khalil, attended the International Congr...

2025-12-01 00:07 1764

Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

-  Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to...

2025-11-30 18:15 2047
1 ... 11121314151617 ... 395

Week's Top Stories